Table 4.

Number of stage III colorectal cancer patients and difference in rate of receiving adjuvant chemotherapy between the presence and absence of pre‐existing diabetes mellitus per regimen type

Regimen types	Without DM (n = 5,078)		With DM (n = 1,266)		Adjusted † difference in rate between patients without and with DM, percentage points (95% CI)
	Received (n)	Rate of adjuvant chemotherapy (%)	Received (n)	Rate of adjuvant chemotherapy (%)
Platinum‐containing regimens ‡	1,188	23.4	208	16.4	4.2 (2.0, 6.5)
Other regimens §	1,805	35.5	423	33.4	0.4 (−2.5, 3.3)

^† Adjusted for age, sex, Charlson Comorbidity Index, type of hospital (Designated Cancer Care Hospitals or others) and prefecture where hospitals are located using the generalized linear model.

^‡ Platinum‐containing regimens include FOLFOX (folinic acid, fluorouracil, and oxaliplatin), CapeOX (capecitabine and oxaliplatin), UFT + LV + L‐OHP (tegafur/uracil, leucovorin, and oxaliplatin) and S‐1 + Plt (tegafur/gimeracil/oteracil and platinating agent).

^§ Other regimens include UFT + LV (tegafur/uracil and leucovorin), 5FU + LV (fluorouracil and leucovorin), Cape (capecitabine), S‐1 (tegafur/gimeracil/oteracil) and FOLFIRI (folic acid, fluorouracil, and irinotecan).

CI, confidence interval; CRC, colorectal cancer; DM, diabetes mellitus.